AstraZeneca has sold off marketing and development rights to another one of its pipeline assets.
This time it’s Takeda that’s stepping up, inking a deal package totaling $400 million for development and commercialization rights to its home grown MEDI1341, an alpha-synuclein antibody designed to combat Parkinson’s disease.
{iframe}https://endpts.com/astrazeneca-auctions-off-another-pipeline-drug-as-takeda-steps-up-with-a-400m-parkinsons-deal/{/iframe}